CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Cash flows from investing activities:
Acquisition, cash acquired		$ 33,583
Supplemental disclosure of cash flow information:
Cash paid for interest	13,322	15,456
Cash paid for income taxes	0	0
Supplemental disclosure of non-cash financing activity:
Common stock issued for accrued director fees (in shares)	167,086
Shares issued for Director's fees	184,653
Exercise of warrants (in shares)	216,085
Common stock issued for earn-out liability (in shares)	2,632,576
Shares issued for payment of Earn-out liability related to Surgical Biologics	3,185,223	0
Equipment purchased under capital lease	84,650
Conversion of Convertible Secured Promissory Notes related to the acquisition of Surgical Biologics (in shares)	893,267
Shares issued for payment of Line of Credit with related party (in shares)	1,403,630
Shares issued for payment of Line of Credit with related party	1,403,630
Outstanding convertible debt and accrued interest (in shares)		406,664
Shares Issued In Conjunction With Its Acquisition Of Surgical Biologics LLC (in shares)		5,250,000
Stock valued in conjunction with the acquisition of Surgical Biologics, LLC		7,087,500
Proceeds from issuance of Convertible Senior Secured Promissory Notes	1,250,000
Beneficial conversion feature value related to the convertible debt issued with regard to the acquisition of Surgical Biologics, LLC	893,267	437,500
Beneficial conversion feature related to convertible line of credit	514,456	80,000
Beneficial Conversion Feature Value Related To Convertible Debt Issued With Regard To Senior Secured Promissory Notes		2,278,052
Beneficial Conversion Feature Related To Warrants Issued With Regard To Senior Secured Promissory Notes		$ 14,885